Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The acute coronary syndrome treatment market is primarily driven by the rising prevalence of coronary heart disease and other lifestyle-associated disorders, including high cholesterol, diabetes, and obesity.
In July 2022, the combination of highly sensitive troponin testing and combined negative copeptin helped in the early discharge from the ICUs in the United States. This will be helpful in ruling out the risk of the acute coronary syndrome in patients.
In June 2022, a new diagnostic technique, the synthetic intelligence (AI) approach, was developed to detect plaque erosions in coronary arteries and thus help in the early treatment of the acute coronary syndrome.
Acute coronary syndrome is a cardiac disease leading to the partial or complete blockage of blood flow to the heart. This syndrome consists of three subtypes: Unstable Angina, Non-ST-Elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). With time, patients with unstable angina have also been covered under Non-ST-Elevation myocardial infarction due to the increased use of the High Sensitivity Troponin Test.
People with obesity and unhealthy lifestyles are at a higher risk of suffering from acute coronary syndrome. The primary cause of this syndrome is the formation of a blood clots, which is caused due to the rupturing of the plaques (fatty deposits) in and on the walls of coronary arteries and blood vessels.
These blood clots lead to the blockage of blood flow to the heart muscles and thus lead to temporary blockage or even cell death. Other causes of this syndrome are Spontaneous Coronary Artery Dissection and Coronary Artery Spasm.
The signs and symptoms of the acute coronary syndrome include chest pain, dizziness, sudden sweating, fatigue, heart palpitations, and shortness of breath. Physical exams, blood tests, and Electrocardiograms (EKGs) are the primary tests for diagnosing acute coronary syndrome and help record the heart’s electrical activity.
Electrocardiogram tests measure the heart's electrical activity, which helps identify the blockage. Blood tests help determine the concentration of certain enzymes, indicating the heart tissue's status.
Additional imaging tests like Computed Tomography (CT) scans or Heart Magnetic Resonance Imaging (MRI) are also used to produce detailed pictures of the heart. The Cardiac Perfusion Test is also used to determine whether the heart is getting sufficient blood.
Acute coronary syndromes can be treated by a group of medications and surgical procedures to open the blockages. Acute coronary syndrome is more prevalent in men than women due to the different lifestyle patterns.
The increasing inclination of today’s youth toward a sedentary lifestyle increases the risk of acute coronary syndrome. Hence, this can be a promising driving factor in the acute coronary syndrome treatment market growth.
According to the acute coronary syndrome market research report, the market can be categorised into the following segments:
Market Breakup by Indication
Market Breakup by Class
Market Breakup by Treatment Channel
Market Breakup by Region
The value of the acute coronary syndrome treatment market is driven by the rising prevalence of cardiovascular diseases. The number of cardiovascular disorders diagnosed cases was nearly 547 million in 2021. The prevalence of the disease is likely to grow at a rate of 2.3% in the forecast period of 2022-2030. With this growth rate, the number of cases is expected to reach approximately 671 million by 2030.
According to World Health Organization, the global prevalence of acute coronary syndrome was 523 million in 2019, with 17.9 million deaths worldwide . Acute coronary syndrome is most prevalent in the Asia Pacific regions, accounting for more than 50% of the world’s total cases.
This increasing prevalence of cardiovascular disorders and sudden cardiac arrest is responsible for driving the growth of the acute coronary syndrome treatment market. This is stimulating the demand for novel therapeutic options and hence will facilitate market growth.
The clinical algorithms for managing acute coronary syndrome in Australia and New Zealand are generally comparable with Europe and the United States of America. In contrast, the algorithms among the other parts of Asia show mutability according to the situation. Thus, developed nations account for the major burden of the global acute coronary syndrome treatment market.
The acute coronary syndrome (ACS) is more common among the geriatric population. Globally, the highest incidence of acute coronary syndrome have been recorded in Latin American and the Middle Eastern regions.
According to the survey results, the prevalence of acute coronary syndrome will rise in developing countries (China, Sub-Sahara Africa, India, Latin America, and the Far East). The prevalence of ACS is rising in developing countries due to the increased sedentary lifestyle, smoking, and obesity.
Most European countries have significantly decreased the age-standardised death rates for ACS in the last decades. This is due to the improvement of cardiovascular prevention and treatment. Through the studies, it is projected that ACS is more prevalent in blacks than whites. The increased cases of cardiovascular disorders are also boosting the global acute coronary syndrome treatment market growth.
Novel product launches and approvals are also expected to facilitate the expansion of the acute coronary syndrome treatment market. This is contributing to the increased collaborations among the key players and companies. The collaborations will substantially boost the revenue of the acute coronary syndrome treatment market.
Among the types of ACS, non-ST segment elevation has nearly remained constant, while the ST segment elevation has decreased significantly in the last few years. Despite modern advancements in medical and interventional therapies, there is still a substantial increase in new cases and mortalities among people all over the globe.
Acute coronary syndrome is a syndrome caused by the decreased blood flow in the coronary arteries leading to the malfunctioning or death of the heart tissue. This is mainly caused due to the atheroma rupture leading to the blockage of the arteries.
The primary idea behind eradicating acute coronary syndrome is to minimise the symptoms in the short and long run. The treatment is based on three mechanisms- Relieve pain and distress, improve blood flow, and restore heart function in the best way possible.
Depending on the diagnosis, the following types of medications are being prescribed by the health physicians:
If the condition is extreme or the medications fail to work, then there is the need for surgical procedures to restore the blood flow to the heart muscles. The following surgeries may be prescribed:
From an international perspective, the cumulative direct and indirect costs of patients with acute coronary syndrome are estimated to be USD 1.26 million. The average cost per acute coronary syndrome patient in the United States` is USD 10.4 billion annually.
The initial prices are less for medical treatment than for percutaneous coronary intervention and coronary artery bypass graft. But several interventions are required for the chronic term, thus, accounting for increased costs and giving a brighter global acute coronary syndrome treatment market outlook.
With the high treatment potential, there is an excellent opportunity for healthcare industries and pharmaceutical companies in drug development and novel diagnostics methods.
Several clinical trials for ACS are being developed and researched by healthcare organisations and pharma companies. To get a safer and more efficient treatment for acute coronary syndrome, investigators continuously search, analyse, and reformulate current therapies and treatments. They are more drawn toward the study of the new treatment with new targeted therapies.
Clinical trials for Polyprenols were completed in 2018 and seemed to be an effective treatment for acute coronary syndrome at the Russian Institute of Medical Sciences. Apixaban, a drug by Bristol-Myers Squibb, has also undergone Phase 3 clinical trials and can soon be an effective medication for ACS.
Several individual pharmacological agents, such as antiplatelet drugs, β-blockers, ACE inhibitors, and lipid-lowering agents, have also been tested. These combinations have efficiently reduced mortality in patients with acute coronary syndromes.
The antiplatelet agent clopidogrel has also been proven beneficial in treating non-ST-segment elevation acute coronary syndrome patients. Rivaroxaban, a drug funded by Johnson & Johnson Pharmaceutical Research & Development, also reduced the risk of the composite end point of death from the acute coronary syndrome, other cardiovascular causes, myocardial infarction, and stroke. Ticagrelor monotherapy has also been proven to prevent net combined ischemic and bleeding events.
Clinical researchers have also discovered many novel targeted therapies for better management of acute coronary syndrome. In Phase II, clinical trials have also demonstrated promising results from anti-inflammatory agents like tocilizumab and ZD5718.
In early phase trials, antithrombotic agents like Revacept, PZ-128, Vicagrel and Selatogrel have shown excellent results, and some are still in the exploration phase. The tests concluded that Dual Anti-Platelet Therapy would remain the cornerstone strategy for treating acute coronary syndrome. Still, these newly discovered agents can be included as adjunctive agents for the chronic treatment of acute coronary syndrome.
Brilanta, an anti-platelet drug developed by AstraZeneca, treats acute coronary syndrome by decreasing platelet aggregation and preventing blood clots. The Food and Drug Administration also approved the generic version of Plavix to reduce heart attacks or stroke risks in patients with atherosclerosis.
AUGUSTUS trials done by Pfizer in collaboration with Bristol-Myers Squibb gave positive results in Phase 4; soon, this can also be used to treat acute coronary syndrome. Several ongoing clinical trials are emerging as a driving factor for acute coronary syndrome treatment market growth and development.
The report gives an in-depth analysis of the key players involved in the acute coronary syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Acute Coronary Syndrome Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Acute Coronary Syndrome Treatment Market
6.1 Global Acute Coronary Syndrome Treatment Market Overview
6.2 Global Acute Coronary Syndrome Treatment Market Analysis
6.2.1 Market Overview
188.8.131.52 Global Acute Coronary Syndrome Treatment Market Historical Value (2015-2021)
184.108.40.206 Global Acute Coronary Syndrome Treatment Market Forecast Value (2022-2030)
6.3 Global Acute Coronary Syndrome Treatment Market by Indication
6.3.1 Market Overview
220.127.116.11 Unstable Angina
18.104.22.168 ST-Elevation Myocardial Infarction
22.214.171.124 Non-ST-Elevation Myocardial Infarction
6.4 Global Acute Coronary Syndrome Treatment Market by Class
6.4.1 Market Overview
6.5 Global Acute Coronary Syndrome Treatment Market by Treatment Channel
6.5.1 Market Overview
6.6 Global Acute Coronary Syndrome Treatment Market by Region
6.6.1 Market Overview
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
6.6.2 North America
18.104.22.168 Historical Trend (2015-2021)
22.214.171.124 Forecast Trend (2022-2030)
126.96.36.199 Break Up by Country
188.8.131.52.1 United States of America
184.108.40.206 Historical Trend (2015-2021)
220.127.116.11 Forecast Trend (2022-2030)
18.104.22.168 Break Up by Country
22.214.171.124.1 United Kingdom
6.6.4 Asia Pacific
126.96.36.199 Historical Trend (2015-2021)
188.8.131.52 Forecast Trend (2022-2030)
184.108.40.206 Break Up by Country
6.6.5 Latin America
220.127.116.11 Historical Trend (2015-2021)
18.104.22.168 Forecast Trend (2022-2030)
22.214.171.124 Break Up by Country
6.6.6 Middle East and Africa
126.96.36.199 Historical Trend (2015-2021)
188.8.131.52 Forecast Trend (2022-2030)
184.108.40.206 Break Up by Country
220.127.116.11.1 Saudi Arabia
18.104.22.168.2 United Arab Emirates
22.214.171.124.4 South Africa
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials
7.2 Patent Landscape
7.2.1 Patent Overview
126.96.36.199 Patent Status and Expiry
188.8.131.52 Timelines from Drug Development to Commercial Launch
184.108.40.206 New Drug Application
220.127.116.11.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Regulatory Framework
7.4.1 Regulatory Overview
18.104.22.168 US FDA
22.214.171.124 EU EMA
126.96.36.199 INDIA CDSCO
188.8.131.52 JAPAN PMDA
8 Challenges & Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Acute Coronary Syndrome Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives & Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 Pfizer Inc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.2 Sanofi S.A.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.3 GSK plc
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.4 Merck & Co., Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.5 AbbVie Inc.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.6 Amgen Inc.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.7 AstraZeneca plc
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.8 Baxter International Inc.
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.9 Bayer AG
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.10 Biogen Inc.
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.11 C. H. Boehringer Sohn Co. KG
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.12 Eli Lilly and Company
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.13 Gilead Sciences, Inc.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.14 Teva Pharmaceutical Industries Ltd.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
11 Recommendations and Discussion
12 Global Acute Coronary Syndrome Treatment Drugs Distribution Model (Additional Insight)
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
The factors such as the increasing prevalence of cardiovascular disorders, rising geriatric population and novel product launches and approvals are driving the market growth.
Based on the indication, the market is categorised into vial unstable angina, ST-elevation myocardial infarction, and non-ST-elevation myocardial infarction, among others.
Based on the class, the market is bifurcated into anti-hypertensive, antithrombotic, and statins, among others.
The treatment channels in this market are public and private.
The different regions in the acute coronary syndrome treatment market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The three types of acute coronary syndrome are Unstable Angina, Non-ST-Elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI).
Acute coronary syndrome is a cardiac disease leading to the partial or complete blockage of blood flow to the heart.
Acute coronary syndrome is caused due to the formation of a blood clot resulting from the rupturing of the plaques (fatty deposits) in and on the walls of coronary arteries and blood vessels.
Heart attack is also a part of acute coronary syndrome.
The treatment options for acute coronary syndrome include: Thrombolytics or Anti Coagulating agents, Nitroglycerins, Antiplatelet drugs, Beta-blockers, ACE inhibitors, Angiotensin receptor blockers and Statins.
The Asia Pacific region has the highest incidence of acute coronary syndrome.
Physical exams, Blood tests and Electrocardiograms (EKGs) are the primary tests for diagnosing acute coronary syndrome and help record the heart’s electrical activity.
Yes, acute coronary syndrome can be treated by following the prescribed medication schedule and altering lifestyle patterns.
Healthcare providers may recommend surgery for reopening the artery to restore normal blood flow.
The key companies involved in this market are Pfizer Inc., Sanofi S.A., GSK plc, Merck & Co., Inc., Amgen Inc., Arena Pharmaceuticals, AstraZeneca plc, Baxter International Inc., Bayer AG, Biogen Inc., C. H. Boehringer Sohn Co. KG, Eli Lilly and Company, Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.